Literature DB >> 29769976

CATMAT statement on disseminated strongyloidiasis: Prevention, assessment and management guidelines.

A K Boggild1,2,3, M Libman4, C Greenaway5, A E McCarthy6.   

Abstract

BACKGROUND: Strongyloides stercoralis is a parasitic nematode found in humans, with a higher prevalence in tropical and sub-tropical regions worldwide. If untreated, the infection can progress to disseminated strongyloidiasis, a critical illness which may be fatal.
OBJECTIVE: To provide clinical guidance on the prevention, assessment and management of disseminated strongyloidiasis.
METHODS: A literature review was conducted to evaluate the current evidence and to identify any systematic reviews, case reports, guidelines and peer reviewed and non-peer reviewed medical literature. The Committee to Advise on Tropical Medicine and Travel (CATMAT) assembled a working group to develop this statement, which was then critically reviewed and approved by all CATMAT members. RECOMMENDATIONS: CATMAT recommends that screening for strongyloidiasis should be considered for individuals with epidemiologic risk and/or co-morbidities that place them at risk for Strongyloides hyperinfection and dissemination. Those at highest risk of hyperinfection and dissemination are individuals born in a Strongyloides-endemic area who undergo iatrogenic immunosuppression or have intercurrent human T-lymphotropic virus (HTLV-1) infection. Diagnosis of strongyloidiasis is based on serologic testing and/or examination of stools and other clinical specimens for larvae. Referral to a tropical medicine specialist with expertise in the management of strongyloidiasis is recommended for suspected and confirmed cases. A diagnosis and treatment algorithm for strongyloidiasis has been developed as a reference tool.
CONCLUSION: Strongyloidiasis is relatively widespread in the global migrant population and screening for the disease should be based on an individual risk assessment. A practical tool for the clinician to use in the prevention, assessment and management of disseminated strongyloidiasis in Canada is now available.

Entities:  

Year:  2016        PMID: 29769976      PMCID: PMC5864421          DOI: 10.14745/ccdr.v42i01a03

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  27 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

2.  Steroid therapy and strongyloidiasis.

Authors:  A J Willis; C Nwokolo
Journal:  Lancet       Date:  1966-06-25       Impact factor: 79.321

3.  Fatal strongyloidiasis in patients receiving corticosteroids.

Authors:  T Cruz; G Reboucas; H Rocha
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

4.  The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States.

Authors:  P Muennig; D Pallin; C Challah; K Khan
Journal:  Epidemiol Infect       Date:  2004-12       Impact factor: 2.451

Review 5.  Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management.

Authors:  Sue Lim; Kevin Katz; Sigmund Krajden; Milan Fuksa; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

Review 6.  Detection and treatment of Strongyloides hyperinfection syndrome following lung transplantation.

Authors:  A Balagopal; L Mills; A Shah; A Subramanian
Journal:  Transpl Infect Dis       Date:  2009-02-22       Impact factor: 2.228

7.  Travel-acquired infections in Canada: CanTravNet 2011-2012.

Authors:  A K Boggild; J Geduld; M Libman; B J Ward; A McCarthy; J Hajek; W Ghesquiere; J Vincelette; S Kuhn; D O Freedman; K C Kain
Journal:  Can Commun Dis Rep       Date:  2014-09-18

Review 8.  Strongyloides stercoralis: Global Distribution and Risk Factors.

Authors:  Fabian Schär; Ulf Trostdorf; Federica Giardina; Virak Khieu; Sinuon Muth; Hanspeter Marti; Penelope Vounatsou; Peter Odermatt
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11

9.  Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis and bronchial asthma: a case report.

Authors:  Levent Altintop; Burcu Cakar; Murat Hokelek; Ahmet Bektas; Levent Yildiz; Muge Karaoglanoglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-09-20       Impact factor: 3.944

10.  Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.

Authors:  Yupin Suputtamongkol; Nalinee Premasathian; Kid Bhumimuang; Duangdao Waywa; Surasak Nilganuwong; Ekkapun Karuphong; Thanomsak Anekthananon; Darawan Wanachiwanawin; Saowaluk Silpasakorn
Journal:  PLoS Negl Trop Dis       Date:  2011-05-10
View more
  23 in total

1.  Case Report: Two Cases of Strongyloidiasis Presenting with Thrombotic Events.

Authors:  Mara Waters; Sigmund Krajden; Christie Kim; Reem Elsobky; Bohdan Lychacz; Matthew Cheung; Mark Crowther; Jay Keystone
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

2.  Evaluation of Strongyloides Awareness and Knowledge among Canadian Physicians Caring for Patients At Risk for Severe Strongyloidiasis: A National Cross-sectional Survey.

Authors:  Samuel De l'Étoile-Morel; Faheel Naeem; Mohammad Alghounaim; Makeda Semret; Cedric P Yansouni; Michael D Libman; Sapha Barkati
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

Review 3.  Current Effective Therapeutics in Management of COVID-19.

Authors:  Kavya Atluri; Iris Aimlin; Shitij Arora
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

4.  Case Report: Central Nervous System Strongyloidiasis: Two Cases Diagnosed Antemortem.

Authors:  Jennifer Tam; Kevin L Schwartz; Jay Keystone; Dimitri Dimitrakoudis; Mark Downing; Sigmund Krajden
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

5.  Molecular and Immnune Diagnosis: Further Testing for Human Strongyloidiasis.

Authors:  Larissa R Bosqui; Priscilla D Marques; Gessica B de Melo; Maria do Rosário F Gonçalves-Pires; Fernanda M Malta; Wander R Pavanelli; Ivete Conchon-Costa; Julia M Costa-Cruz; Fabiana M Paula; Idessania N Costa
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

6.  Case Report: Ivermectin and Albendazole Plasma Concentrations in a Patient with Disseminated Strongyloidiasis on Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Authors:  Carl Boodman; Yashpal S Chhonker; Daryl J Murry; Allison Mah; Jennifer Grant; Theodore Steiner; Michael Libman; Cesilia Nishi; Marthe Charles
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

7.  Safety culture implications on safe work practices and work place exposure incidents in Operation Theater.

Authors:  Tahira Hameed; Eitezaz Ahmed Bashir; Abdul Qadeer Khan; Murtaza Ahmad
Journal:  Pak J Med Sci       Date:  2021 Mar-Apr       Impact factor: 1.088

8.  Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome.

Authors:  Sabrina H M Yeung; Omar Mourad; Michael Klowak; Adrienne J Showler; Stefanie Klowak; Andrea K Boggild
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-04-03

9.  A case of fatal disseminated strongyloidiasis accompanied with intestinal obstruction.

Authors:  Peyman Heydarian; Iraj Mobedi; Mohamad Ali Mohaghegh; Abozar Hosseini; Fatemeh Goudarzvand Chegini; Bahman Rahimi Esboei
Journal:  Oxf Med Case Reports       Date:  2019-10-14

10.  Corticosteroids in Covid-19 pandemic have the potential to unearth hidden burden of strongyloidiasis.

Authors:  Disha Gautam; Ayush Gupta; Adarsh Meher; Farha Siddiqui; Abhishek Singhai
Journal:  IDCases       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.